Skip to main content
. 2019 Sep 6;11:8229–8238. doi: 10.2147/CMAR.S213931

Figure 1.

Figure 1

Effect of eltrombopag (EP) and/or decitabine (DAC) on the viability of myeloid leukemia cells. (A) Viability of K562 cells incubated with EP (2.5, 5, 10 and 30 μg/mL) alone for 24, 48, 72 and 96 hrs. (B) Viability of K562 cells cultured with DAC (0.5, 5, 10 and 20 μmol/L) alone for 24, 48, 72 and 96 hrs. (C) Viability of THP-1 cells incubated with EP (2.5, 5, 10 and 30 μg/mL) alone for 24, 48, 72 and 96 hrs. (D) Viability of THP-1 cells cultured with DAC (0.5, 5, 10 and 20 μmol/L) alone for 24, 48, 72 and 96 hrs. (E) Viability of K562 cells treated with EP plus DAC (2.5 μg/mL EP +20 μmol/L DAC, 5 μg/mL EP +20 μmol/L DAC, 10 μg/mL EP +20 μmol/L DAC and 30 μg/mL EP +20 μmol/L DAC) for 24, 48, 72 and 96 hrs. (F) Viability of THP-1 cells treated with EP (2.5, 5, 10 and 30 μg/mL) combined with DAC (20 μmol/L) for 24, 48, 72 and 96 hrs. Data are represented as the mean ± SD (****p<0.0001; ***p<0.001; **p<0.01; *p<0.05).